(Shanghai/Suzhou/Beijing, China) on January 19, 2022, Duality Biologics reached a strategic cooperation agreement with Harbour BioMed (Stock Code: 02142. HK). According to the agreement, Harbour BioMed will grant the self-developed preferred monoclonal antibody for specific tumor targets to Duality Biologics for the exclusive development of ADC medicines in the world. Based on the DITAC (Duality Immune Toxin Antibody Conjugate) technology platform with its independent intellectual property rights, Duality Biologics will rapidly develop the world's first-in-class ADC medicines to benefit patients all over the world. And Harbour BioMed will receive the down payment, milestone payments and sales-based royalties paid by Duality Biologics.
Harbour BioMed and Duality Biologics always maintain a strategic win-win cooperative relationship. After signing the agreement, both parties will continue to uphold the common goal of rapid research and development of high-quality ADC: Duality Biologics will be responsible for the preclinical research, clinical development, clinical registration, production and commercialization of the ADC candidate molecule; Harbour BioMed will continue to pay close attention to the relevant follow-up research of this molecule and provide necessary support.
“Previously, fully human antibodies developed from Harbour Mice® have been used in multiple company's ADCs development projects, demonstrating the advantages of our fully human antibodies in ADC development. With Duality Biologics' strong R&D advantages in ADC development, this strategic collaboration will further strengthen our overall strategy in the field of ADC, maximize the value of Harbour Mice®, develop more high-quality and differentiated new ADC drugs to meet global patients' needs.” said Dr. Jingsong Wang, Founder, Chairman and CEO of Harbour BioMed.
“I'm very pleased to achieve strategic collaboration with Harbour BioMed, and we are both very excited and confident about this new target of ADC drug. The combination of our proprietary ADC platform in next-generation and tumor-specific antibody will optimize the value of our DITAC platform, a leading 3rd generation toxin ADC platform with significantly improved therapeutic window, and rapidly enrich our pipeline to generate original innovative products. The signing of this agreement is the beginning of our platform-based strategic win-win cooperation. In the future, Duality Biologics hopes to maintain the close cooperation with Harbour BioMed and continue to propel more product development, jointly bringing better therapeutics to patients.” said Dr. John Zhu, founder and CEO of Duality Biologics.
About Harbour BioMed
Harbour BioMed (HKEX: 02142) is a global biopharmaceutical company committed to the discovery, development and commercialization of novel antibody therapeutics focusing on oncology and immunology. The Company is building its robust portfolio and differentiated pipeline through internal R&D capability, collaborations with co-discovery and co-development partners and select acquisitions.
The Company's proprietary antibody technology platforms Harbour Mice® generate fully human monoclonal antibodies in two heavy and two light chain (H2L2) format, as well as heavy chain only (HCAb) format. Building upon the HCAb antibodies, the HCAb-based immune cell engagers (HBICE®) are capable of delivering tumor killing effects unachievable by traditional combination therapies. Integrating Harbour Mice® with single B cell cloning platform, our antibody discovery engine is highly unique and efficient for development of next generation therapeutic antibodies.
About Duality Biologics
"To Translate Novel Modality into Reality". Duality Biologics was founded in January 2020 by Dr. John Zhu, a well-respected investor in the healthcare industry. Duality Biologics is committed to developing novel modality drugs to fulfill the unmet medical needs for patients worldwide. Focusing on novel technology platforms and innovative medicines for cancer and autoimmune diseases, Duality Biologics has successfully established a number of next-generation Antibody-Drug Conjugate (ADC) technology platforms with global intellectual property rights. These include DITAC (Duality Immune Toxin Antibody Conjugate), DIMAC (Duality Immune Modulating Antibody Conjugate) and DISAC (Duality Immune Stimulating Antibody Conjugate). Duality Biologics has successfully built a robust pipeline of more than 10 best-in-class and/or first-in-class ADC programs, of which several drug candidates are in the IND stage. Duality Biologics will continue to establish rich product pipelines to benefit patients through the independent research and strategic collaboration.